Search Results
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Phase I/II study of elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, in patients with KRAS G12C mutation–positive (G12Cmut) non–small cell lung cancer (NSCLC). The data were presented in a Clinical Science Symposium at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago,
More news about: D3 Bio
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These landmark findings will be featured in a Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Professor Shun Lu, Director of the Lung Cancer Center at Shanghai Chest
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO™ with LAZCLUZE®
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
reactions, permanently discontinue ERLEADA [see Dosage and Administration (2.2)].Interstitial Lung Disease (ILD)/Pneumonitis — Fatal and life-threatening interstitial lung disease (ILD) or pneumonitis can occur in patients treated with ERLEADA.Post-marketing cases of ILD/pneumonitis,
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease
More news about: Eli Lilly and Company
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
cervical, colorectal, and lung cancers (USPSTF A and B recommendations) led to a 6.5 fold increase in the number of cancers found by screening. Galleri detected nearly three times as many cancers when added to standard-of-care screening for breast, cervical, colorectal, lung, and prostate cancers (USPSTF
More news about: GRAIL, Inc.
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. One study evaluated DZD6008, an investigational fourth-generation
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
/美通社/ -- 2026年5月31日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」6990.HK)宣布，公司自主研發的靶向人滋養細胞表面抗原2(TROP2)的抗體偶聯藥物(ADC)蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期臨床研究(OptiTROP-Lung05)結果榮登國際頂級醫學期刊《柳葉刀》（The
More news about: 科倫博泰
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
-- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also
More news about: Kelun-Biotech
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
potential of targeting seizure related homolog protein 6 (SEZ6) with a next-generation ADC for the treatment of neuroendocrine tumors, including small cell lung cancer (SCLC). These data will be presented in a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
group of 12 deadly cancers2 when the Galleri test was added to standard of care screening in England (breast, bowel, cervical and high risk lung cancers) versus standard of care screening alone; however, there was no statistically significant difference within a 1-year follow up window after
More news about: GRAIL, Inc.
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
2026年5月30日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」 6990.HK)宣佈，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，同濟大學附屬東方醫院周彩存教授以口頭報告形式公佈了TROP2 ADC蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期OptiTROP-Lung05研究結果(摘要編號#8506，肺癌-轉移性非小細胞)。
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).
More news about: Kelun-Biotech
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application
More news about: Kelun-Biotech
May 29, 2026, 19:05 ET Brayton Purcell LLP Highlights Investigative Report on California's Silicosis Crisis Linked to Artificial Stone
provided by affected workers during a May 21 public hearing in Los Angeles, where regulators heard firsthand accounts of severe respiratory disease, lung transplants, and shortened life expectancy."This reporting gives voice to workers whose experiences are too often reduced to statistics," said
More news about: Brayton Purcell LLP
May 29, 2026, 17:48 ET Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
effect on overall survival.National Analysis Finds Income-Related Gaps in Lung Cancer Survival Have Widened Since Screening Guidelines Introduced (Abstract 8072)A new national study suggests that while lung cancer screening has helped more patients receive earlier diagnoses and live longer,
More news about: NYU Langone Health System
May 29, 2026, 17:31 ET Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 17:30 ET Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400's differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjugate optimization for radiotherapies in the context of the Company's pipeline
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 16:47 ET Celebrate World Digestive Health Day With Gundry MD Bio Complete 3, A Unique Supplement That Is Redefining Gut Health Support
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. doi:10.1016/S1470-2045(15)00026-1 7
More news about: Johnson & Johnson
May 29, 2026, 10:20 ET Future of Cancer Care Launches Nationwide
(NCCN®)Personalized Medicine Coalition (PMC)Union for International Cancer Control (UICC)SurvivorNetGO2 for Lung CancerAgilent TechnologiesSpecial Editorial SpotlightThe campaign features beloved TODAY anchor and broadcaster Al Roker
More news about: Mediaplanet
May 29, 2026, 09:00 ET The $13 Million Company Teaching the Immune System to Hunt Cancer
dose escalation, then expands into a "basket" across as many as seven solid tumor types — prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder. In the company's own framing, the solid-tumor patient population GTB-5550 targets is "orders of magnitude larger" than the
More news about: USA News Group
May 29, 2026, 08:52 ET Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based
More news about: Dizal Pharmaceutical
May 29, 2026, 06:10 ET Allegheny Health Network's Allegheny General Hospital Once Again Earns Elite 3‑Star Rating for Cardiac Surgery Excellence, Placing it Among the Top Programs Nationwide
surgeons, researchers, and allied healthcare professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society's mission is to enhance the ability of cardiothoracic surgeons to
More news about: Allegheny Health Network
May 28, 2026, 19:00 ET Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and thoracic cancers, such as lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.About Pfizer:
More news about: Innovent Biologics